Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Kazia Therapeutics Limited before investing.

In this article, we go over a few key elements for understanding Kazia Therapeutics Limited’s stock price such as:

• Kazia Therapeutics Limited’s current stock price and volume
• Why Kazia Therapeutics Limited’s stock price changed recently
• Upgrades and downgrades for KZIA from analysts
• KZIA’s stock price momentum as measured by its relative strength

About Kazia Therapeutics Limited (KZIA)

Before we jump into Kazia Therapeutics Limited’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3 that is in Phase I clinical trial to treat advanced solid tumors and ovarian cancer. The company has collaborations with the Australian and New Zealand Children’s Haematology/Oncology Group, Genentech Inc., Global Coalition for Adaptive Research, Vivesto AB, Simcere Pharmaceutical Group Ltd, Evotec SE, Sovargen Co., Ltd, and QIMR Berghofer Medical Research Institute. Kazia Therapeutics Limited was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

Want to learn more about Kazia Therapeutics Limited’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Kazia Therapeutics Limited.

Kazia Therapeutics Limited’s Stock Price as of Market Close

As of January 15, 2026, 1:18 PM, CST, Kazia Therapeutics Limited’s stock price was $7.175.

Kazia Therapeutics Limited is up 4.44% from its previous closing price of $6.870.

During the last market session, Kazia Therapeutics Limited’s stock traded between $6.511 and $7.250. Currently, there are approximately 0.88 million shares outstanding for Kazia Therapeutics Limited.

Kazia Therapeutics Limited’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Kazia Therapeutics Limited Stock Price History

Kazia Therapeutics Limited’s (KZIA) price is currently up 4.14% so far this month.

During the month of January, Kazia Therapeutics Limited’s stock price has reached a high of $7.250 and a low of $5.000.

Over the last year, Kazia Therapeutics Limited has hit prices as high as $17.400 and as low as $2.860. Year to date, Kazia Therapeutics Limited’s stock is up 4.14%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Kazia Therapeutics Limited Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of January 14, 2026, there were analysts who downgraded Kazia Therapeutics Limited’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate Kazia Therapeutics Limited’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Kazia Therapeutics Limited’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Kazia Therapeutics Limited (KZIA) by visiting AAII Stock Evaluator.

Relative Price Strength of Kazia Therapeutics Limited

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of January 14, 2026, Kazia Therapeutics Limited has a weighted four-quarter relative price strength of 8.56%, which translates to a Momentum Score of 77 and is considered to be Strong.

Want to learn more about how Kazia Therapeutics Limited is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Kazia Therapeutics Limited Stock Price: Bottom Line

As of January 15, 2026, Kazia Therapeutics Limited’s stock price is $7.175, which is up 4.44% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Kazia Therapeutics Limited stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.